Literature DB >> 20832051

Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Terence C Chua1, Winston Liauw, Akshat Saxena, Khalid Al-Mohaimeed, Salawan Fransi, Jing Zhao, David L Morris.   

Abstract

BACKGROUND: Peritoneal carcinomatosis imposes an enormous clinical burden to the oncologic community. This study reports the patterns of care of the locoregional approach of cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy as a curative procedure for peritoneal carcinomatosis from the experience of a single tertiary center in Australia.
METHODS: We performed a review of clinical records from a prospective database of patients who were treated at the St George Hospital Peritoneal Surface Malignancy Program according to a standard protocol.
RESULTS: A total of 308 CRS were performed in 249 patients with peritoneal surface malignancy; the mean age was 53 years and 55% were women. Over the years, we expanded the age limit for treatment (P = .03), reduced intensive care unit stays (P = .04), reduced amount of blood transfusion (P = .03), treated patients with a higher peritoneal cancer index (P < .001), achieved higher rates of complete cytoreduction (P = .003), increased use of PIC (P < .001), and improved complication rate (P = .02) and mortality rate (P = .01). The median survival of patients treated over the years also improved (P = .001).
CONCLUSIONS: We show the maturity of the treatment of peritoneal carcinomatosis with CRS and perioperative intraperitoneal chemotherapy in our institution after an initial learning curve with expansion of the selection criteria, improved perioperative outcomes, improved surgical results, and long-term survival outcomes. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20832051     DOI: 10.1016/j.amjsurg.2010.02.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

Authors:  P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.

Authors:  David S Sparks; Bradley Morris; Wen Xu; Jessica Fulton; Victoria Atkinson; Brian Meade; Nicholas Lutton
Journal:  Int Surg       Date:  2015-01

Review 3.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

4.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis.

Authors:  Reese W Randle; Katrina R Swett; Perry Shen; John H Stewart; Edward A Levine; Konstantinos I Votanopoulos
Journal:  Am Surg       Date:  2013-06       Impact factor: 0.688

5.  The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Samer A Naffouje; Kiara A Tulla; Zaynab Khalaf; George I Salti
Journal:  J Gastrointest Oncol       Date:  2019-04

6.  The influence of goal-directed fluid therapy on the prognosis of elderly patients with hypertension and gastric cancer surgery.

Authors:  Kai Zeng; Yanzhen Li; Min Liang; Youguang Gao; Hongda Cai; Caizhu Lin
Journal:  Drug Des Devel Ther       Date:  2014-10-29       Impact factor: 4.162

7.  Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Experience in Peritoneal Carcinomatosis: Single-Center Analysis of 180 Cases.

Authors:  Kursat Karadayi; Meric Emre Bostanci; Murat Can Mollaoglu; Ufuk Karabacak
Journal:  Int J Surg Oncol       Date:  2021-04-22

Review 8.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.

Authors:  Chao-Qun Huang; Yao Min; Shu-Yi Wang; Xiao-Jun Yang; Yang Liu; Bin Xiong; Yutaka Yonemura; Yan Li
Journal:  Oncotarget       Date:  2017-04-27

Review 9.  The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors.

Authors:  Yi Cheng; Shanshan Weng; Linzhen Yu; Ning Zhu; Mengyuan Yang; Ying Yuan
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.